Search research articles
Contact Us
Filters
Showing results (11-20 of 68) with videos related to
Page
of 7
Sort By:
International Journal of Rheumatology
|
April 6, 2017
Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis
Evelien Bergrath, Robert A Gerber, David Gruben, et al.
RMD Open
|
June 3, 2025
Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies
Dafna Gladman, William Tillett, David Gruben, et al.
Journal of Clinical Pharmacology
|
March 26, 2009
Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers
Nervin Lawendy, Sriram Krishnaswami, Rong Wang, et al.
Digestive Diseases and Sciences
|
August 28, 2023
Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database
Michael Chiorean, Christina Ha, Peter Hur, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
December 2, 2016
Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
Josef S Smolen, Daniel Aletaha, David Gruben, et al.
Arthritis Care & Research
|
August 27, 2016
Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial
Vibeke Strand, Joel M Kremer, David Gruben, et al.
Dermatology and Therapy
|
November 12, 2020
The Economic and Psychosocial Comorbidity Burden Among Adults with Moderate-to-Severe Atopic Dermatitis in Europe: Analysis of a Cross-Sectional Survey
Giampiero Girolomoni, Thomas Luger, Audrey Nosbaum, et al.
Dermatology and Therapy
|
March 29, 2022
Clinical and Humanistic Burden of Atopic Dermatitis in Europe: Analyses of the National Health and Wellness Survey
Thomas Luger, William A Romero, David Gruben, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
February 17, 2026
Burden of Mild-to-Moderate Atopic Dermatitis in Adults in the United States: Results from the National Health and Wellness Survey
Jonathan I Silverberg, Wendy Smith Begolka, Zelma C Chiesa Fuxench, et al.
Inflammatory Bowel Diseases
|
September 28, 2019
Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States
Millie D Long, Timothy W Smith, Marco Dibonaventura, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 68) with videos related to
Sort By:
Page
of 7
International Journal of Rheumatology
|
April 6, 2017
Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis
Evelien Bergrath, Robert A Gerber, David Gruben, et al.
RMD Open
|
June 3, 2025
Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies
Dafna Gladman, William Tillett, David Gruben, et al.
Journal of Clinical Pharmacology
|
March 26, 2009
Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers
Nervin Lawendy, Sriram Krishnaswami, Rong Wang, et al.
Digestive Diseases and Sciences
|
August 28, 2023
Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database
Michael Chiorean, Christina Ha, Peter Hur, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
December 2, 2016
Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
Josef S Smolen, Daniel Aletaha, David Gruben, et al.
Arthritis Care & Research
|
August 27, 2016
Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial
Vibeke Strand, Joel M Kremer, David Gruben, et al.
Dermatology and Therapy
|
November 12, 2020
The Economic and Psychosocial Comorbidity Burden Among Adults with Moderate-to-Severe Atopic Dermatitis in Europe: Analysis of a Cross-Sectional Survey
Giampiero Girolomoni, Thomas Luger, Audrey Nosbaum, et al.
Dermatology and Therapy
|
March 29, 2022
Clinical and Humanistic Burden of Atopic Dermatitis in Europe: Analyses of the National Health and Wellness Survey
Thomas Luger, William A Romero, David Gruben, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
February 17, 2026
Burden of Mild-to-Moderate Atopic Dermatitis in Adults in the United States: Results from the National Health and Wellness Survey
Jonathan I Silverberg, Wendy Smith Begolka, Zelma C Chiesa Fuxench, et al.
Inflammatory Bowel Diseases
|
September 28, 2019
Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States
Millie D Long, Timothy W Smith, Marco Dibonaventura, et al.
Page
of 7